

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBLT-CELL CROSSMATCHING RESULTS OF SAMPLE 2A07/2014

DESPATCHED ON 15TH JULY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A29; B7, -: Cw7, Cw15; DR4, DR11; DQ7, DQ8

Summary of Results					Summary of Results				
Total tested	41	43	43	43	30	32	32	32	
Positive	10	0	6	1	7	0	4	0	
Negative	31	43	37	42	23	32	28	32	
Not Tested / Equivocal	10	8	8	8	6	4	4	4	
% Positive	24.4%	0.0%	14.0%	2.3%	23.3%	0.0%	12.5%	0.0%	
% Negative	75.6%	100.0%	86.0%	97.7%	76.7%	100.0%	87.5%	100.0%	
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
HLA Antibody (Defined By CDC)	Cw2	DR1	DR52	A9, DR15	Cw2	DR1	DR52	A9, DR15	
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	NT	NT	NT	NT	NT	NT	NT	NT	Low viability
114	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
116	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
117	Positive	Negative	Positive	Negative					The weak reaction seen at serum 1 is seen at 4 degrees, it weakens at 25 degrees and it is negative at 37 degrees. Therefore it is possibly IgM.
119	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
120	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
126	Positive	Negative	Negative	Negative					
128	NT	NT	NT	NT					Viability too low - sample seems to be contaminated by microorganisms
136	Negative	Negative	Negative	Negative					
139	NT	NT	NT	NT	NT	NT	NT	NT	Low cell viability
143	NT	NT	NT	NT					Poor viability
145	Negative	Negative	Negative	Negative					
147	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
149	Negative	Negative	Positive	Negative					
154	Negative	Negative	Negative	Negative					Presence of red blood cells
159	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
162	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
164	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
169	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
174	NT	NT	NT	NT					Viability was poor (<50%) and the cells showed bacterial contamination. This was informed to the scheme director by e-mail
181	Negative	Negative	Negative	Negative					
186	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
189	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
190	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
193	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
194	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
195	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
197	NT	NT	NT	NT	NT	NT	NT	NT	Viability 50%
202	NT	NT	NT	NT	NT	NT	NT	NT	Insufficient viable cells
204	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
206	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
209	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
210	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
216	NT	NT	NT	NT					Not tested because of massive cell death
223	Negative	Negative	Negative	Negative					
227	NT	Negative	Negative	Negative	NT	Negative	Negative	Negative	NT: not enough serum volume to test with and without DTT
229	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
232	Negative	Negative	Negative	Negative					
235	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Cell viability was very low
238	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
243	Negative	Negative	Negative	Negative					
245	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
252	Negative	Negative	Weak Positive	Negative	Negative	Negative	Weak Positive	Negative	
259	Negative	Negative	Negative	Negative					
260	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
262	Equivocal	Negative	Negative	Negative	Equivocal	Negative	Negative	Negative	
268	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
293	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
294	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
297	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A07/2014

DESPATCHED ON 15TH JULY 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used PBL	T-cells	Immunobeaded cells used?	Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells	
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						PBL	T-cells		pre C'	post C'		
112	NT	NT	NT	NT	NT	NT	NT	NT	18-Jul	18-Jul	Yes		No	50		Cedarlane	60	120	Stain fix	
114	4	1	1	1	6	1	1	1	16-Jul	17-Jul		Yes	Yes			One Lambda	30	60	Fluoroquench	
116	1	1	1	1	1	1	1	1	16-Jul	17-Jul		Yes	No		98	Cedarlane	20	60	EB/AO	
117	2	1	2	1					17-Jul	17-Jul	Yes		No	80		Pel-Freeze	60	120	Fluoroquench	
119	4	1	4	1	1	1	4	1	16-Jul	16-Jul	Yes		No	95		Biorad	30	60	Eosin staining	
120	1	1	1	1	1	1	1	1	16-Jul	17-Jul	Yes		Yes		100	Servbio	30	60	Fluoroquench	
126	25%	-	-	-					17-Jul	17-Jul		Yes	Yes		100	Cedarlane	30	40	EB/AO	
128	NT	NT	NT	NT					16-Jul	18-Jul	Yes		No	20		One Lambda	45	90	Stain fix	
136	1	1	1	1					16-Jul	16-Jul	Yes		Yes		95	In-house	60	60	EB/AO	
139	NT	NT	NT	NT	NT	NT	NT	NT	17-Jul	18-Jul	Yes	Yes	Yes	10	10	Cedarlane	30	60	Eosine	
143	NT	NT	NT	NT					17-Jul	18-Jul		Yes	Yes		70					
145	-	-	-	-					16-Jul	17-Jul		Yes	Yes		100	Invitrogen	45	45	EB/AO	
147	1	1	1	1	1	1	1	1	16-Jul	16-Jul		Yes	Yes		100	In-house	30	60	Fluoroquench	
149	-	-	4	-					16-Jul	18-Jul	Yes				90				Eosin stain fix	
154	1	1	1	1					16-Jul	17-Jul		Yes	No		90	Cedarlane	30	60	Eosin staining	
159	1	1	1	1	1	1	1	1	16-Jul	16-Jul		Yes	Yes		99	In-house	30	60	Fluoroquench	
162	4	-	-	-	4	-	-	-	16-Jul	16-Jul		Yes	Yes		100	Cedarlane	60	60	Fluoroquench	
164									16-Jul	17-Jul		Yes	Yes		90	Servbio	45	90	Fluoroquench	
169	8	1	1	1	8	1	1	1	16-Jul	17-Jul		Yes	Yes		98	In-house	35	75	Fluoroquench	
174	NT	NT	NT	NT					18-Jul	19-Jul	Yes		No	50		One Lambda	60	120	Eosin stain	
181	1	1	1	1					16-Jul	16-Jul	Yes		No	85		Cedarlane	30	45		
186	2	0	0	0	2	0	0	0	16-Jul	17-Jul		Yes	Yes		99	Invitrogen	30	60	Fluoroquench	
189	1	1	2	1	1	1	2	1	17-Jul	18-Jul	Yes		No	90		Biorad	40	40	EB/AO	
190	2%	2%	2%	2%	5%	5%	5%	5%	16-Jul	16-Jul		Yes	Yes		98	Cedarlane	30	60	Fluoroquench	
193	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	Yes	No	99	99	Cedarlane	30	60		
194	1	1	1	1	1	1	1	1	16-Jul	17-Jul		Yes	Yes		95	In-house	30	45	Fluoroquench	
195	4	4	4	4					18-Jul	18-Jul	Yes		No	50		Invitrogen	30	60	Fluoroquench	
197	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	
202	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	
204	1	1	1	1	1	1	1	1	17-Jul	17-Jul		Yes	No		90	Cedarlane	45	90	Fluoroquench	
206	1	1	1	1	1	1	1	1	17-Jul	17-Jul		Yes	Yes		100	Cedarlane	30	45	Fluoroquench	
209	-	-	-	-	-	-	-	-	16-Jul	16-Jul	Yes		No	90		Ingen	30	60	Fluoroquench	
210	0	0	0	0	0	0	0	0	17-Jul	17-Jul		Yes	Yes		100	Biorad	30	60		
216	NT	NT	NT	NT					17-Jul	18-Jul	Yes		No	30		Biorad	30	60	PI	
223	1	1	1	1					18-Jul	21-Jul		Yes	Yes		95	Biorad	45	60	EB/AO	
227	NT	-	-	-	NT	-	-	-	16-Jul	16-Jul		Yes	Yes		98	Immucor	30	60	Fluoroquench	
229	-	-	-	-	-	-	-	-	17-Jul	17-Jul	Yes		No	70		Cedarlane	30	60		
232	-	-	-	-					17-Jul	17-Jul	Yes		No	70		Biotest	45	60	Fluoroquench	
235	1	1	4	1	1	1	2	1	16-Jul	16-Jul	Yes		No	80		Biorad	30	60	Eosin	
238	4	1	1	1	4	1	1	1	16-Jul	17-Jul		Yes	Yes		95	95	Invitrogen	45	90	Fluoroquench
243	2	2	2	2					16-Jul	17-Jul	Yes		Yes		90	80	Biorad	30	60	Fluoroquench
245	1	1	1	1	1	1	1	1	16-Jul	16-Jul	Yes	Yes	Yes	100	100	BAG	30	60	EB/AO	
252	1-2	1-2	2-4	1-2	1-2	1-2	2-4	1-2	17-Jul	17-Jul		Yes	No		60	One Lambda	30	60		
259	-	-	-	-					17-Jul	17-Jul	Yes	Yes	Yes	70	85	Biorad	30	60	AO/PI	
260	++	-	-	-	++	-	-	-	17-Jul	17-Jul		Yes	Yes		90	Biorad	30	60	EB/AO	
262	2	-	-	-	-	-	-	-	17-Jul	17-Jul	Yes	Yes	Yes	90	90	Invitrogen	30	60	Eosin staining	
268	1	1	1	1	1	1	1	1	16-Jul	16-Jul		Yes	No		90	Gentrak	30	60	EB/AO	
284	1	1	1	1	2	1	1	1	16-Jul	16-Jul		Yes	Yes		98	Cedarlane	40	60	EB/AO	
293	-	-	-	-	-	-	-	-	17-Jul	17-Jul		Yes	Yes		80	Invitrogen	60	120	Eosin	
294	0	0	0	0	0	0	0	0	16-Jul	17-Jul		Yes	Yes		100	Pel-Freeze	30	30	Fluoroquench	
297	1	1	2	1	1	1	2	1	17-Jul	17-Jul		Yes	Yes		>90	>90	Cedarlane	30	60	Fluoroquench

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A07/2014

DESPATCHED ON 15TH JULY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A29; B7, -; Cw7, Cw15; DR4, DR11; DQ7, DQ8

Summary of Results					Summary of Results (Not assessed)				
Total tested	28	31	32	32	22	24	25	25	
Positive	10	4	30	0	6	3	23	1	
Negative	18	27	2	32	16	21	2	24	
Not Tested / Equivocal	9	6	5	5	8	5	5	5	
% Positive	35.7%	12.9%	93.8%	0.0%	27.3%	12.5%	92.0%	4.0%	
% Negative	64.3%	87.1%	6.3%	100.0%	72.7%	87.5%	8.0%	96.0%	
Consensus	Not Assessed	Negative	Positive	Negative	Not Assessed	Negative	Positive	Negative	
HLA Antibody (Defined By CDC)	Cw2	DR1	DR52	A9, DR15	Cw2	DR1	DR52	A9, DR15	
Lab No.	Serum 1	Without DTT			With DTT (Not assessed)				Comments
		Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
114	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Low BL count, viability less than 50% together with interferences did not allow a reliable microscope reading Not done due to poor cell viability with DTT: 80% Viability 50% Insufficient viable cells Scored 8 for serum 3 but high background subtracted Not tested due to low viability NT: not enough serum volume to test with and without DTT.
120	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
126	Positive	Negative	Positive	Negative					
139	NT	NT	NT	NT	NT	NT	NT	NT	
145	Positive	Negative	Positive	Negative					
147	Equivocal	Positive	Positive	Negative	Equivocal	Positive	Positive	Negative	
154	NT	NT	NT	NT					
159	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Positive	
162	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
164	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
169	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
181	Negative	Negative	Positive	Negative					
186	Equivocal	Positive	Positive	Negative	Negative	Negative	Positive	Negative	
190	Negative	Negative	Positive	Negative	NT	NT	NT	NT	
193	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
194	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
195	Negative	Negative	Positive	Negative	NT	NT	NT	NT	
197	NT	NT	NT	NT	NT	NT	NT	NT	
202	NT	NT	NT	NT	NT	NT	NT	NT	
204	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
206	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
209	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
210	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
223	NT	NT	NT	NT					
227	NT	Negative	Positive	Negative	NT	Negative	Positive	Negative	
238	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative	
243	Negative	Negative	Positive	Negative					
245	Equivocal	Negative	Positive	Negative	Equivocal	Negative	Positive	Negative	
252	Negative	Negative	Weak Positive	Negative	Negative	Negative	Weak Positive	Negative	
259	Positive	Negative	Positive	Negative					
260	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
262	Positive	Equivocal	Positive	Negative	Positive	Negative	Positive	Negative	
268	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
284	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
293	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
294	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
297	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A07/2014

DESPATCHED ON 15TH JULY 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
114	1	1	4	1	1	1	4	1	16-Jul	17-Jul	Yes		One Lambda	30	60	Fluoroquench
120	1	1	8	1	1	1	8	1	16-Jul	17-Jul	Yes	100	Servibio	30	60	Fluoroquench
126	25%	-	75%	-	NT	NT	NT	NT	17-Jul	17-Jul	Yes	100	Cedarlane	30	40	EB/AO
139	NT	NT	NT	NT	NT	NT	NT	NT	17-Jul	18-Jul	Yes	10	Cedarlane	30	60	Eosine
145	4-6	-	8	-	16-Jul	17-Jul	Yes	80	Invitrogen	45	45	EB/AO				
147	2	4	8	1	16-Jul	16-Jul	Yes	90	In-house	30	60	Fluoroquench				
154	NT	NT	NT	NT	16-Jul	17-Jul	No	50	Cedarlane	30	60	Eosin staining				
159	6	6	8	1	16-Jul	16-Jul	Yes	99	In-house	30	60	Fluoroquench				
162	4	-	8	-	16-Jul	16-Jul	Yes	100	Cedarlane	60	60	Fluoroquench				
164					16-Jul	17-Jul	Yes	90	Servibio	45	90	Fluoroquench				
169	1	1	1	1	16-Jul	17-Jul	Yes	98	In-house	35	75	Fluoroquench				
181	2	2	8	1	16-Jul	16-Jul	Yes	85	Cedarlane	30	45					
186	2	2	8	0	16-Jul	17-Jul	Yes	99	Invitrogen	30	60	Fluoroquench				
190	2%	2%	100%	2%	NT	NT	NT	NT	16-Jul	16-Jul	Yes	95	Cedarlane	30	60	Fluoroquench
193	1	1	8	1	16-Jul	16-Jul	Yes	95	Cedarlane	30	60					
194	1	1	8	1	16-Jul	17-Jul	Yes	95	In-house	30	45	Fluoroquench				
195	4	4	8	4	18-Jul	18-Jul	Yes	50	Invitrogen	60	90	Fluoroquench				
197	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
202	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
204	1	1	4	1	17-Jul	17-Jul	No	20	Cedarlane	45	90	Fluoroquench				
206	1	1	8	1	17-Jul	17-Jul	Yes	70	Cedarlane	30	45	Fluoroquench				
209	-	-	8	-	16-Jul	16-Jul	Yes	90	Ingen	30	60	Fluoroquench				
210	0	0	+++	0	17-Jul	17-Jul	Yes	80	Biorad	30	60					
223	NT	NT	NT	NT	18-Jul	21-Jul	Yes	50	Biorad	45	60	EB/AO				
227	NT	-	8	-	16-Jul	16-Jul	Yes	98	Immucor	30	60	Fluoroquench				
238	8	4	8	1	16-Jul	17-Jul	Yes	85	Invitrogen	45	90	Fluoroquench				
243	2	2	8	2	16-Jul	17-Jul	Yes	80	Biorad	30	60	Fluoroquench				
245	2	1	8	1	16-Jul	16-Jul	Yes	100	BAG	30	45	EB/AO				
252	1-2	1-2	2-4	1-2	17-Jul	17-Jul	Yes	40	One Lambda	30	60					
259	-	-	-	-	17-Jul	17-Jul	Yes	80	Biorad	30	60	AO/PI				
260	++	-	++++	-	17-Jul	17-Jul	Yes	85	Biorad	30	60	EB/AO				
262	6	-	8	-	17-Jul	17-Jul	Yes	90	Invitrogen	60	90	Eosin staining				
268	1	1	8	1	16-Jul	16-Jul	Yes	60	Gentrak	30	60	EB/AO				
284	4	1	8	1	16-Jul	16-Jul	Yes	85	Cedarlane	40	60	EB/AO				
293	-	-	6	-	17-Jul	17-Jul	Yes	80	Invitrogen	60	120	Eosin				
294	0	0	8	0	16-Jul	17-Jul	Yes	100	Pel-Freeze	30	30	Fluoroquench				
297	1	1	2	1	17-Jul	17-Jul	Yes	>90	Cedarlane	30	60	Fluoroquench				